Dense breasts with a normal mammogram — supplemental MRI, ultrasound, notification and the USPSTF honesty clause

Examiner prompts with model answers

Density first — risk and mask. Dense tissue is an independent risk factor and it lowers mammographic sensitivity — the two-word reason her normal mammogram reassures less than average.^[24]

DENSE — the numbers you must carry. In 40,373 Dutch women with extremely dense breasts, MRI invitation cut interval cancers from 5.0 to 2.5 per 1000; 59% accepted, detection ran 16.5 per 1000 in scanned women, false positives 79.8 per 1000, predictive value 17.4% for recall and 26.3% for biopsy. Offer with both halves quoted.^[21]

Abbreviated MRI versus DBT — the head-to-head. EA1141 in dense breasts: invasive detection 11.8 versus 4.8 per 1000, sensitivity 95.7 versus 39.1%, specificity 86.7 versus 97.4%. MRI is the most sensitive test she can buy and the least specific — consent the recalls, not just the cancers.^[22]

Ultrasound's fenced role. Adjunct ultrasound improves detection of small node-negative invasive cancers, from Connecticut 2009 to the 2019 federal mandate — operator-dependent, biopsy-generating, and a complement rather than a competitor to MRI.^[23]

What notification changed. US density laws lifted supplemental screening use by 0.5 to 143%, biopsy rates by up to 4% and detection by up to 11% — a systems effect: expect busier assessment clinics wherever notification lands.^[24]

The USPSTF honesty clause. Despite DENSE, the Task Force calls supplemental ultrasound or MRI evidence insufficient after a negative mammogram in dense breasts — interval cancers are not mortality, and saying so is the distinction-marker answer.^[2]

Reading her next report. Walk the BI-RADS ladder: 0 recalls, 1 to 2 routine, 3 surveillance, 4 (4A 7.6, 4B 22, 4C 69.3%) biopsies, 5 plans surgery, 6 stages known cancer — and benign core against 4C or 5 imaging means re-biopsy, never reassurance.^[27]

Were she a BRCA carrier — different pathway entirely. Pre-surgery surveillance is overwhelmingly MRI from age 18 to 30 with 6-to-12-monthly examination across 22 centres in 16 countries — earlier, more intensive, and guideline-owned, not extrapolated from DENSE.^[45]